A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Erythematosus

Summary

This study will evaluate the pharmacokinetic characteristics and safety of belimumab subcutaneous (SC) in Chinese pediatric participants with SLE who have completed 48 weeks belimumab Intravenous (IV) treatment in 213560 study (NCT04908865)

Timeline

Start

2023-07-07

Primary completion

2024-10-30

Completion

2024-10-30

Drugs

Indications